PT100980B - Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao - Google Patents
Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao Download PDFInfo
- Publication number
- PT100980B PT100980B PT100980A PT10098092A PT100980B PT 100980 B PT100980 B PT 100980B PT 100980 A PT100980 A PT 100980A PT 10098092 A PT10098092 A PT 10098092A PT 100980 B PT100980 B PT 100980B
- Authority
- PT
- Portugal
- Prior art keywords
- protein
- ospa
- gene
- borrelia
- lipoprotein
- Prior art date
Links
- 208000016604 Lyme disease Diseases 0.000 title claims abstract description 34
- 241000589968 Borrelia Species 0.000 title claims abstract description 25
- 229960005486 vaccine Drugs 0.000 title claims abstract description 9
- 238000001514 detection method Methods 0.000 title claims description 3
- 206010061591 Borrelia infection Diseases 0.000 title claims 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 title abstract description 8
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 title abstract description 8
- 238000004519 manufacturing process Methods 0.000 title description 13
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 113
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 76
- 108090001030 Lipoproteins Proteins 0.000 claims abstract description 61
- 102000004895 Lipoproteins Human genes 0.000 claims abstract description 57
- 239000003599 detergent Substances 0.000 claims abstract description 47
- 108700006640 OspA Proteins 0.000 claims abstract description 22
- IDOQDZANRZQBTP-UHFFFAOYSA-N 2-[2-(2,4,4-trimethylpentan-2-yl)phenoxy]ethanol Chemical compound CC(C)(C)CC(C)(C)C1=CC=CC=C1OCCO IDOQDZANRZQBTP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 229920004929 Triton X-114 Polymers 0.000 claims abstract description 13
- 239000000203 mixture Substances 0.000 claims abstract description 10
- 239000013600 plasmid vector Substances 0.000 claims abstract description 7
- 239000004094 surface-active agent Substances 0.000 claims abstract description 5
- 230000001939 inductive effect Effects 0.000 claims abstract description 4
- 239000013612 plasmid Substances 0.000 claims description 49
- 101150045801 ospA gene Proteins 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 31
- 239000012071 phase Substances 0.000 claims description 31
- 101150107995 ACA1 gene Proteins 0.000 claims description 23
- 241000588724 Escherichia coli Species 0.000 claims description 23
- 229940099789 ospa protein Drugs 0.000 claims description 20
- 238000000746 purification Methods 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 11
- 108010077805 Bacterial Proteins Proteins 0.000 claims description 9
- 239000000872 buffer Substances 0.000 claims description 8
- 238000005191 phase separation Methods 0.000 claims description 8
- 238000000926 separation method Methods 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 5
- 241000701867 Enterobacteria phage T7 Species 0.000 claims description 4
- 230000027455 binding Effects 0.000 claims description 4
- 230000008014 freezing Effects 0.000 claims description 4
- 238000007710 freezing Methods 0.000 claims description 4
- 239000007790 solid phase Substances 0.000 claims description 4
- 238000013518 transcription Methods 0.000 claims description 4
- 230000035897 transcription Effects 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 241001198387 Escherichia coli BL21(DE3) Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002158 endotoxin Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000003550 marker Substances 0.000 claims description 2
- 238000010257 thawing Methods 0.000 claims description 2
- 230000014621 translational initiation Effects 0.000 claims description 2
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 230000000717 retained effect Effects 0.000 claims 1
- 241000589969 Borreliella burgdorferi Species 0.000 abstract description 12
- 230000014616 translation Effects 0.000 abstract description 4
- 238000004440 column chromatography Methods 0.000 abstract description 2
- 239000000284 extract Substances 0.000 abstract description 2
- 238000010438 heat treatment Methods 0.000 abstract description 2
- 238000003149 assay kit Methods 0.000 abstract 1
- 101710105714 Outer surface protein A Proteins 0.000 description 74
- 235000018102 proteins Nutrition 0.000 description 53
- 241000699670 Mus sp. Species 0.000 description 28
- 150000002632 lipids Chemical group 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 15
- 230000005847 immunogenicity Effects 0.000 description 13
- 150000007523 nucleic acids Chemical class 0.000 description 13
- 238000003752 polymerase chain reaction Methods 0.000 description 13
- 108020004707 nucleic acids Proteins 0.000 description 12
- 102000039446 nucleic acids Human genes 0.000 description 12
- 210000002966 serum Anatomy 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 11
- 102000036639 antigens Human genes 0.000 description 11
- 239000013615 primer Substances 0.000 description 11
- 108091034117 Oligonucleotide Proteins 0.000 description 10
- 239000000427 antigen Substances 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 239000012634 fragment Substances 0.000 description 10
- 229920002271 DEAE-Sepharose Polymers 0.000 description 9
- 241000589970 Spirochaetales Species 0.000 description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 238000010367 cloning Methods 0.000 description 9
- 230000012010 growth Effects 0.000 description 9
- 239000008188 pellet Substances 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 8
- 230000006698 induction Effects 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 229920002684 Sepharose Polymers 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 210000004899 c-terminal region Anatomy 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 239000006166 lysate Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 230000029087 digestion Effects 0.000 description 5
- 239000001963 growth medium Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 239000013504 Triton X-100 Substances 0.000 description 4
- 229920004890 Triton X-100 Polymers 0.000 description 4
- 239000013592 cell lysate Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 3
- 229940037003 alum Drugs 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000007928 solubilization Effects 0.000 description 3
- 238000005063 solubilization Methods 0.000 description 3
- 238000002255 vaccination Methods 0.000 description 3
- QENJLXATANVWMR-UHFFFAOYSA-N 2-[(3-amino-3-imino-2-methylpropanethioyl)amino]acetic acid Chemical compound NC(=N)C(C)C(=S)NCC(O)=O QENJLXATANVWMR-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 101710137500 T7 RNA polymerase Proteins 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000003119 immunoblot Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 210000004897 n-terminal region Anatomy 0.000 description 2
- 238000005192 partition Methods 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 101710154825 Aminoglycoside 3'-phosphotransferase Proteins 0.000 description 1
- 101001086191 Borrelia burgdorferi Outer surface protein A Proteins 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- 108091033380 Coding strand Proteins 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 1
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 1
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- 108090000233 Signal peptidase II Proteins 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 101150049515 bla gene Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960005091 chloramphenicol Drugs 0.000 description 1
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 229960003964 deoxycholic acid Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002196 fr. b Anatomy 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 125000003473 lipid group Chemical group 0.000 description 1
- 230000004576 lipid-binding Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000005354 penicillin allergy Diseases 0.000 description 1
- 230000001323 posttranslational effect Effects 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229940079862 sodium lauryl sarcosinate Drugs 0.000 description 1
- ADWNFGORSPBALY-UHFFFAOYSA-M sodium;2-[dodecyl(methyl)amino]acetate Chemical group [Na+].CCCCCCCCCCCCN(C)CC([O-])=O ADWNFGORSPBALY-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 206010048282 zoonosis Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77904891A | 1991-10-18 | 1991-10-18 | |
US88876592A | 1992-05-27 | 1992-05-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
PT100980A PT100980A (pt) | 1994-01-31 |
PT100980B true PT100980B (pt) | 1999-07-30 |
Family
ID=27119531
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT100980A PT100980B (pt) | 1991-10-18 | 1992-10-16 | Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0620860A4 (xx) |
JP (1) | JPH06511154A (xx) |
AU (1) | AU676140B2 (xx) |
CA (1) | CA2121121C (xx) |
FI (1) | FI941749A (xx) |
IL (1) | IL103462A0 (xx) |
NO (1) | NO310417B1 (xx) |
PT (1) | PT100980B (xx) |
WO (1) | WO1993008299A1 (xx) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4015911A1 (de) | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
US6676942B1 (en) | 1991-08-15 | 2004-01-13 | Smithkline Beecham Biologicals (S.A.) | Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines |
AU666326B2 (en) * | 1991-08-15 | 1996-02-08 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines |
CA2105629A1 (en) * | 1992-09-14 | 1994-03-15 | Robert S. Becker | Potentiation of immunogenic response |
US7008625B2 (en) | 1993-11-01 | 2006-03-07 | Research Foundation Of The State University Of New York | Recombinant constructs of Borrelia burgdorferi |
US6248562B1 (en) | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
US6610838B1 (en) | 1997-09-10 | 2003-08-26 | Symbicom Aktiebolag | P13 antigens from Borrelia |
US6224882B1 (en) | 1997-11-07 | 2001-05-01 | Protein Science Corp. | Insect cells or fractions as adjuvant for antigens |
GB9811219D0 (en) * | 1998-05-26 | 1998-07-22 | Smithkline Beecham Biolog | Novel process |
EP1173577A2 (en) * | 1999-04-21 | 2002-01-23 | Boston Medical Center Corporation | Prevention, diagnosis and treatment of lyme disease |
EP1311540B1 (en) | 2000-08-18 | 2007-12-19 | Research Foundation Of State University Of New York | Altered ospa of borrelia burgdorferi |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK590288D0 (da) * | 1988-10-24 | 1988-10-24 | Symbicom Ab | Kemiske forbindelser |
DE4015911A1 (de) * | 1989-09-19 | 1991-03-28 | Max Planck Gesellschaft | Impfstoff gegen die lyme-krankheit |
ES2092560T5 (es) * | 1989-12-22 | 2004-09-16 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Proteinas inmunologicamente activas de borrelia burgdorferi, estuches de ensayo relacionados y vacuna. |
CA2057536C (en) * | 1990-12-21 | 1999-10-26 | John J. Dunn | Cloning and expression of borrelia lipoproteins |
AU666326B2 (en) * | 1991-08-15 | 1996-02-08 | Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts | Osp A proteins of borrelia burgdorferi subgroups, encoding genes and vaccines |
-
1992
- 1992-10-16 WO PCT/US1992/008697 patent/WO1993008299A1/en not_active Application Discontinuation
- 1992-10-16 JP JP5507751A patent/JPH06511154A/ja active Pending
- 1992-10-16 AU AU28011/92A patent/AU676140B2/en not_active Ceased
- 1992-10-16 PT PT100980A patent/PT100980B/pt not_active IP Right Cessation
- 1992-10-16 EP EP92922390A patent/EP0620860A4/en not_active Withdrawn
- 1992-10-16 CA CA002121121A patent/CA2121121C/en not_active Expired - Fee Related
- 1992-10-18 IL IL103462A patent/IL103462A0/xx unknown
-
1994
- 1994-04-15 NO NO19941376A patent/NO310417B1/no not_active IP Right Cessation
- 1994-04-15 FI FI941749A patent/FI941749A/fi unknown
Also Published As
Publication number | Publication date |
---|---|
JPH06511154A (ja) | 1994-12-15 |
CA2121121C (en) | 2003-06-10 |
NO941376D0 (no) | 1994-04-15 |
CA2121121A1 (en) | 1993-04-29 |
FI941749A0 (fi) | 1994-04-15 |
EP0620860A1 (en) | 1994-10-26 |
AU2801192A (en) | 1993-05-21 |
WO1993008299A1 (en) | 1993-04-29 |
NO941376L (no) | 1994-06-17 |
EP0620860A4 (en) | 1997-05-02 |
AU676140B2 (en) | 1997-03-06 |
PT100980A (pt) | 1994-01-31 |
NO310417B1 (no) | 2001-07-02 |
IL103462A0 (en) | 1993-03-15 |
FI941749A (fi) | 1994-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Fairweather et al. | Immunization of mice against tetanus with fragments of tetanus toxin synthesized in Escherichia coli | |
JP5566684B2 (ja) | Clostridiumdifficileに対する、組換え毒素A/毒素Bワクチン | |
Erdile et al. | Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA | |
Dunn et al. | Outer surface protein A (OspA) from the Lyme disease spirochete, Borrelia burgdorferi: high level expression and purification of a soluble recombinant form of OspA | |
US5846946A (en) | Compositions and methods for administering Borrelia DNA | |
US5571718A (en) | Cloning and expression of soluble truncated variants of Borrelia OspA, OspB and Vmp7 | |
JPH11502415A (ja) | モラクセラ属(Moraxella)の高分子量主要外膜タンパク | |
JPH072696A (ja) | ライム病を予防するための方法及び組成物 | |
WO1990015871A1 (en) | Expression of tetanus toxin fragment c | |
PT832093E (pt) | Expressão de lipoproteínas | |
KR20200024895A (ko) | 합성 폴리펩타이드 에피토프 기반의 백신 조성물 | |
PT100980B (pt) | Proteinas recombinantes de borrelia, seu processo de producao, vacina contra infeccao por borrelia e agente de imunodiagnostico para a sua deteccao | |
US7144580B2 (en) | M. haemolytica outer membrane protein P1pE as a vaccine or vaccine component against shipping fever | |
JP2762310B2 (ja) | ストレプトコッカルmプロテイン由来の合成ペプタイド及び当該ペプタイドから調製されたワクチン | |
Cullen et al. | Construction and evaluation of a plasmid vector for the expression of recombinant lipoproteins in Escherichia coli | |
JP4599354B2 (ja) | 大腸菌熱不安定性エンテロトキシンサブユニットに融合した志賀毒素サブユニットまたは志賀毒素様毒素サブユニットを含むハイブリッド毒素およびそのワクチン | |
JPH06292581A (ja) | トレポネーマ・ヒオジセンテリエ ワクチン | |
Woollard et al. | Synthetic peptides induce antibody against a host-protective antigen of Echinococcus granulosus | |
Dallas et al. | Identification and purification of a recombinant Treponema pallidum basic membrane protein antigen expressed in Escherichia coli | |
Boyden et al. | Cloning and characterization of Treponema hyodysenteriae antigens and protection in a CF-1 mouse model by immunization with a cloned endoflagellar antigen | |
KR950031108A (ko) | 백신으로서 정제된 분류가능하지 않은 헤모필루스 인플루엔자 p5 단백질, 및 그의 정제 방법 | |
Schmidt et al. | Gal-Gal pyelonephritis Escherichia coli pili linear immunogenic and antigenic epitopes. | |
JP3135060B2 (ja) | ヘモフィルスインフルエンザb型菌の外皮膜タンパク質P2の部分断片を用いた接合体 | |
US7794734B2 (en) | Mannheimia haemolytica chimeric outer membrane protein PlpE and leukotoxin epitopes as a vaccine or vaccine component against shipping fever | |
WO1990015132A2 (en) | Cloned treponema hyodysenteriae endoflagellar antigen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
BB1A | Laying open of patent application |
Effective date: 19930701 |
|
FG3A | Patent granted, date of granting |
Effective date: 19990416 |
|
MM3A | Annulment or lapse |
Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20031031 |